tetano
Editor, Senior Moderator
J Clin Microbiol. 2012 Feb 29. [Epub ahead of print]
Evaluation of the Cepheid(R) Xpert(R) Flu Assay for Rapid Identification and Differentiation of Influenza A, Influenza A 2009 H1N1, and Influenza B.
Novak-Weekley SM, Marlowe EM, Poulter M, Dwyer D, Speers D, Rawlinson W, Baleriola C, Robinson CC.
Source
Southern California Permanente Medical Group, North Hollywood, CA.
Abstract
The Xpert Flu cartridge represents a next generation nucleic acid amplification system that provides multiplexed PCR detection of influenza A, influenza A 2009 H1N1, and influenza B in approximately 70 minutes with minimal hands-on time. Six laboratories participated in a clinical trial to compare the new Cepheid Xpert Flu Assay to the results of culture or real-time PCR on archived and prospectively collected nasal aspirate-wash (NA-W) specimens and nasopharyngeal (NP) swabs from children and adults. Discrepant results were resolved by DNA sequence analysis. After discrepant analysis the sensitivity of the Xpert Flu Assay for prospective NA-W specimens containing influenza A, influenza A 2009 H1N1, and influenza B compared to culture was 90.0%, 100%, and 100% respectively, while the sensitivity of the assay for prospective NP swabs compared to culture was 100%, 100%, and 100% respectively. The sensitivity of the Xpert Flu for archived NA-W specimens compared to Gen-Probe ProFlu+ PCR for influenza A, influenza A 2009 H1N1, and influenza B was 99.4%, 98.4%, and 100%, respectively, while the sensitivity of the Xpert Flu for archived NP swabs compared to ProFlu+ was 98.1%, 100%, and 93.8% respectively. The sensitivity of the Xpert Flu for archived NP specimens compared to culture for the three targets was 97.5%, 100%, and 93.8%, respectively. We conclude that the Cepheid Xpert Flu Assay is an accurate and rapid method that is suitable for on-demand testing for influenza viral infection.
PMID:
22378908
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22378908
Evaluation of the Cepheid(R) Xpert(R) Flu Assay for Rapid Identification and Differentiation of Influenza A, Influenza A 2009 H1N1, and Influenza B.
Novak-Weekley SM, Marlowe EM, Poulter M, Dwyer D, Speers D, Rawlinson W, Baleriola C, Robinson CC.
Source
Southern California Permanente Medical Group, North Hollywood, CA.
Abstract
The Xpert Flu cartridge represents a next generation nucleic acid amplification system that provides multiplexed PCR detection of influenza A, influenza A 2009 H1N1, and influenza B in approximately 70 minutes with minimal hands-on time. Six laboratories participated in a clinical trial to compare the new Cepheid Xpert Flu Assay to the results of culture or real-time PCR on archived and prospectively collected nasal aspirate-wash (NA-W) specimens and nasopharyngeal (NP) swabs from children and adults. Discrepant results were resolved by DNA sequence analysis. After discrepant analysis the sensitivity of the Xpert Flu Assay for prospective NA-W specimens containing influenza A, influenza A 2009 H1N1, and influenza B compared to culture was 90.0%, 100%, and 100% respectively, while the sensitivity of the assay for prospective NP swabs compared to culture was 100%, 100%, and 100% respectively. The sensitivity of the Xpert Flu for archived NA-W specimens compared to Gen-Probe ProFlu+ PCR for influenza A, influenza A 2009 H1N1, and influenza B was 99.4%, 98.4%, and 100%, respectively, while the sensitivity of the Xpert Flu for archived NP swabs compared to ProFlu+ was 98.1%, 100%, and 93.8% respectively. The sensitivity of the Xpert Flu for archived NP specimens compared to culture for the three targets was 97.5%, 100%, and 93.8%, respectively. We conclude that the Cepheid Xpert Flu Assay is an accurate and rapid method that is suitable for on-demand testing for influenza viral infection.
PMID:
22378908
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22378908